Posted: July 11, 2024 at 2:43 am
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update highlighting recent developments of note.
Link:
Creative Medical Technology Holdings Provides Corporate Update
Posted: July 11, 2024 at 2:43 am
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health
See the original post:
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
Posted: July 11, 2024 at 2:43 am
AMSTERDAM, July 10, 2024 (GLOBE NEWSWIRE) -- This randomized, controlled trial was conducted at a tertiary IVF center, Ho Chi Minh City, Vietnam. Between January 2023 and June 2023, 120 women were randomized. Eligible women were aged 18–37 years with polycystic ovarian syndrome (PCOS). After providing written informed consent, participants were randomized (1:1) to undergo CAPA-IVM with or without FSH-priming. Participants in the FSH-priming group received two days of recombinant FSH (rFSH) injections before oocyte pick-up; no rFSH was given in the non-FSH group. All retrieved cumulus oocyte complexes underwent biphasic in vitro maturation (CAPA-IVM). Matured oocytes underwent fertilization through ICSI procedure, and were cultured to blastocyst stage followed by vitrification. Participants underwent a single blastocyst transfer during a frozen replacement cycle. The primary endpoint was the number of matured oocytes.
The rest is here:
FSH-free versus FSH-primed infertility treatment of women with polycystic ovary syndrome using biphasic in vitro maturation: a randomized clinical...
Posted: July 11, 2024 at 2:43 am
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment –
Posted: July 11, 2024 at 2:43 am
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s Management Information Circular dated May 31, 2024 (“Circular”) were elected as directors of the Company at the Company’s Annual General Meeting of Shareholders held on July 10, 2024 (“Meeting”).
Link:
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
Posted: July 11, 2024 at 2:43 am
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
See more here:
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
Posted: July 11, 2024 at 2:43 am
MELBOURNE, Australia, July 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments for diagnostic radiopharmaceuticals1 for Medicare patients in the United States (U.S.), facilitating continued patient access after transitional pass-through payment status expires.
Go here to read the rest:
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
Posted: July 11, 2024 at 2:43 am
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
Follow this link:
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
Posted: July 11, 2024 at 2:43 am
PARIS, FRANCE, 11 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation and metastasis. This novel tumor antigen was identified using Foreseen’s high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms, to analyze their vast collection of well-characterized clinical tumor samples. FS001 utilized an innovative, stable and cleavable linker coupled to a potent topoisomerase I inhibitor. Preclinical efficacy of FS001 was demonstrated in multi-drug resistant cancer models. The agreement gives Ipsen exclusive worldwide rights to develop, manufacture and commercialize FS001.
Read this article:
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
Posted: July 11, 2024 at 2:43 am
Jul 11, 2024 11:14:00
by
Large-scale clinical trials in South Africa and Uganda have shown that a new PrEP (pre-exposure prophylaxis) drug called lenacapavir, given as an injection once every six months, can 100% prevent HIV infection. Professor Linda Gayle Becker, deputy director of the Desmond Tutu HIV Centre at the University of Cape Town's Institute of Infectious Diseases and Molecular Medicine, explains lenacapavir and its clinical trials.
HIV breakthrough: drug trial shows injection twice a year is 100% effective against infection https://theconversation.com/hiv-breakthrough-drug-trial-shows-injection-twice-a-year-is-100-effective-against-infection-233295
HIV is a retrovirus that causes acquired immune deficiency syndrome (AIDS). HIV infects and destroys T cells and macrophages, which are responsible for the immune system, resulting in the loss of cell-mediated immunity.
It is estimated that 1.3 million people worldwide will be newly infected with HIV in 2023 alone, and if things continue as they are, the goal of eradicating AIDS by 2030 will not be achieved. On the other hand, PrEP drugs are not a surefire preventative treatment, and they have a high hurdle in that they must be taken every day to be effective.
In order for the virus to grow, it must inject its genetic information into the chromosomes of the cell after infecting it. At this time, the genetic information is wrapped in a protein shell called a capsid. Lenacapavir, developed by the pharmaceutical company Gilead Sciences, has a different mechanism of action from conventional PrEP, and by inhibiting the production of this capsid, it has the effect of suppressing the growth of HIV.
Lenacapavir is taken orally or by subcutaneous injection. Subcutaneous injection is said to be effective even if taken once every six months, which is an advantage over conventional PrEP drugs.
The clinical trial, conducted by the Desmond Tutu HIV Centre at the University of Cape Town's Institute of Infectious Diseases and Molecular Medicine, involved 5,000 female subjects aged 16 to 25 at three sites in Uganda and 25 sites in South Africa. According to the research team, young women in eastern and southern Africa are particularly at the forefront of HIV infection and are often unable to take PrEP medication daily for social reasons.
by Prachatai
The results of the clinical trial showed that none of the 2,134 people taking lenacapavir became infected with HIV, confirming 100% efficacy, compared with 16 of 1,068 people taking Truvada and 39 of 2,136 people taking Descovy who became infected with HIV.
Twice-yearly HIV prevention drug 'Lenacapavir' shows 100% efficacy in HIV prevention in Phase III clinical trial - GIGAZINE
'We hope that this new drug will be adopted into WHO and national guidelines, and that it will begin to be tested in more studies to better understand how to implement it in real-world situations,' said Professor Becker.
In addition, the subjects in this clinical trial were only women, but the research team said that further trials are required to investigate whether the effect differs depending on the style of sexual intercourse that is the route of infection.
See more here:
What is Lenacapavir, the new HIV prevention drug that showed 100% efficacy in clinical trials? - GIGAZINE
